Evidence map›Paper›PMID 40960752›Full record

Observational studyRevista do Colegio Brasileiro de Cirurgioes2025

Assessment of the interval between diagnosis and definitive treatment of lung cancer at a public institution in São Paulo.

Otavio Rocha Fiuza, Barbara Siqueira Souto Maior, Luísa Beisman DE Moraes, Daniel Augusto Xavier Carvalho, João Aléssio Juliano Perfeito, Ernesto Evangelista Neto, André Miotto

Abstract readObservational Study
In one paragraph

Observational study in Revista do Colegio Brasileiro de Cirurgioes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Otavio Rocha Fiuza- Escola Paulista de Medicina/Universidade Federal de São Paulo, Disciplina de Cirurgia Torácica - São Paulo - SP - Brasil.ORCID http://orcid.org/0000-0001-7420-2762
Barbara Siqueira Souto Maior- Escola Paulista de Medicina/Universidade Federal de São Paulo, Disciplina de Cirurgia Torácica - São Paulo - SP - Brasil.ORCID http://orcid.org/0009-0001-8692-4348
Luísa Beisman DE Moraes- Escola Paulista de Medicina/Universidade Federal de São Paulo, Disciplina de Cirurgia Torácica - São Paulo - SP - Brasil.ORCID http://orcid.org/0000-0002-3769-9818
Daniel Augusto Xavier Carvalho- Escola Paulista de Medicina/Universidade Federal de São Paulo, Disciplina de Cirurgia Torácica - São Paulo - SP - Brasil.ORCID http://orcid.org/0009-0000-5262-151X
João Aléssio Juliano Perfeito- Escola Paulista de Medicina/Universidade Federal de São Paulo, Disciplina de Cirurgia Torácica - São Paulo - SP - Brasil.ORCID http://orcid.org/0000-0001-5958-2541
Ernesto Evangelista Neto- Escola Paulista de Medicina/Universidade Federal de São Paulo, Disciplina de Cirurgia Torácica - São Paulo - SP - Brasil.ORCID http://orcid.org/0000-0002-4292-4995
André Miotto- Escola Paulista de Medicina/Universidade Federal de São Paulo, Disciplina de Cirurgia Torácica - São Paulo - SP - Brasil.ORCID http://orcid.org/0000-0002-4260-0595

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to investigate the interval between the diagnosis and definitive surgical treatment of lung cancer patients at a public institution in São Paulo.

methodA retrospective observational study was conducted, using medical records to collect data on the periods between the first abnormal chest computed tomography (CT) scan, the initial consultation with the specialist, and the subsequent tumor resection.

resultsThe analysis of 20 patients revealed a substantial average waiting period of 425.6 days between diagnosis and definitive treatment. During this interval, an average of 282 days elapsed between diagnosis and the initial specialist consultation, while the period between the first consultation and treatment averaged 143 days. By comparing the initial and final staging, 70% of the patients progressed to a higher stage over this period.

conclusionsThe identified interval is concerning and exposes patients to elevated risks during this waiting period. This prolonged duration poses potential threats to patient health, resulting in decreased quality of life, increased risk of disease progression, reduced chances of cure, and diminished overall survival prospects. Addressing and minimizing this extended interval is crucial for improving patient outcomes and enhancing the effectiveness of lung cancer treatment.

Indexed as

Lung NeoplasmsTime-to-TreatmentAdultAgedAged, 80 and overBrazilFemaleHospitals, PublicHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTime FactorsTomography, X-Ray Computed

Identifiers

PMID40960752
PMCPMC12401112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.